Realizing entrepreneurial innovation is the mission of Flagship Ventures. The firm operates through two synergistic units: VentureLabsTM which invents and launches transformative companies, and Venture Capital, which finances and realizes innovative, early-stage companies. Founded in 2000, and based in Cambridge, Massachusetts, Flagship Ventures manages over $900 million in capital. The Flagship team innovates and invests in three principal business sectors: therapeutics, health technologies and sustainability/clean technology. Past successful Flagship portfolio ventures include: Adnexus (acquired by Bristol-Myers Squibb), Accuri Cytometers (acquired by Becton, Dickinson), Morphotek (acquired by Eisai), Color Kinetics (acquired by Philips), AVEO (NASDAQ: AVEO) and BG Medicine (NASDAQ: BGMD). Recent notable portfolio ventures include: Joule Unlimited, Agios, Affinnova, AeroDesigns and Novomer. For more information, please visit www.flagshipventures.com.